Rhinomed Adds US Based Cornerstone Investors and Initiates Capital Management Program
- Undertakes $2.19m private placement to US based Cornerstone investors
- Proposed restructuring of capital through a consolidation on a 1 new share for every 10 shares held basis and the introduction of a Less than Marketable Share Parcel Facility
The placement of 105,135,000 shares will be issued to Mr Whitney George, a current US based sophisticated investor, who has now increased his stake to 17.73% of the company. A further 17,000,000 shares will be issued to one other US based investor group.
The issue price of the placement is 1.8 cents per share which represents a 6% premium to Rhinomed's closing share price of 1.7 cents on the 14th of March and a 16% premium to Rhinomed's 20 day VWAP. All new placement shares will be issued subject to lodgement of a cleansing prospectus by the Company to facilitate secondary trading of shares issued pursuant to the placement.
The capital management initiative seeks to position Rhinomed with international investors through a consolidation of its 936 million issued securities (post the 1.8c placement) to 93.6 million. This is a consolidation of one share for every ten shares held.
The company is also proposing a change to its constitution to allow the sale of less than marketable share parcels, which incur significant administrative costs for the company. This will provide the opportunity for investors with small holdings to easily dispose of their shares in a cost effective manner.
"The strong vote of confidence in the company and its strategy from our cornerstone investors and the capital management initiatives we are introducing sends a clear signal about the direction of Rhinomed. The company is steadily building a compelling strategic position in the global sleep and respiratory markets and an exciting brand presence in the USA. We look forward to sharing an exciting 2017/18 with our shareholders." said Chairman, Ron Dewhurst.
Further details will be included in a Notice of General Meeting that will be despatched to investors following approval from the ASX.
About Rhinomed Limited
Rhinomed Limited (ASX:RNO) is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. Rhinomed is seeking to radically improve the way you breathe, sleep, maintain your health and take medication. The company is rapidly commercializing its platform and has brought two products to market that are now sold globally. For more information, go to www.rhinomed.global